Show simple item record

dc.contributor.authorDearden, S
dc.contributor.authorBrown, H
dc.contributor.authorJenkins, S
dc.contributor.authorThress, K
dc.contributor.authorCantarini, M
dc.contributor.authorCole, R
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorJänne, P
dc.date.accessioned2017-07-30T14:49:41Z
dc.date.available2017-07-30T14:49:41Z
dc.date.issued2017-07
dc.identifier.citationEGFR T790M mutation testing within the osimertinib AURA phase I study. 2017, 109:9-13 Lung Canceren
dc.identifier.issn1872-8332
dc.identifier.pmid28577957
dc.identifier.doi10.1016/j.lungcan.2017.04.011
dc.identifier.urihttp://hdl.handle.net/10541/620462
dc.description.abstractReliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. There is no current consensus regarding the best method to detect EGFR T790M mutations. The aim of this study was to describe the concordance between local testing, which used a variety of methods, and central testing, using the cobas(®) EGFR Mutation Test, for EGFR-sensitizing mutations and the T790M resistance mutation.
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en
dc.titleEGFR T790M mutation testing within the osimertinib AURA phase I study.en
dc.typeArticleen
dc.contributor.departmentPersonalised Healthcare & Biomarkers, AstraZeneca, Cambridgeen
dc.identifier.journalLung Canceren
html.description.abstractReliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. There is no current consensus regarding the best method to detect EGFR T790M mutations. The aim of this study was to describe the concordance between local testing, which used a variety of methods, and central testing, using the cobas(®) EGFR Mutation Test, for EGFR-sensitizing mutations and the T790M resistance mutation.


Files in this item

This item appears in the following Collection(s)

Show simple item record